RXST RxSight, Inc. NASDAQ · United States

RxSight (RXST) news

RxSight, Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker RXST, recorded under United States. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.

Latest RxSight news

We have not published a story on RxSight yet. When there is news, it will appear here.

RxSight annual financials

Line	FY2025	FY2024
Revenue	$134.5 million	$139.9 million
Research and development	$38.5 million	$34.4 million
Net income (loss)	-$38.9 million	-$27.5 million
Cash from operations	-$15.5 million	-$16.9 million
Cash and equivalents	$19.9 million	$16.7 million
Short-term investments	$208.2 million	$220.5 million

Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $13.4 million, plus short-term investments of $195.4 million, $208.8 million in all.

Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice.

Questions about RxSight

What is the ticker symbol of RxSight?

RxSight, Inc. trades under the ticker RXST on NASDAQ.

Where is RxSight listed?

RxSight, Inc. is listed on NASDAQ.

Which country or territory is RxSight listed under?

Our directory records RxSight, Inc. under United States.

Does aibio.space cover RxSight?

aibio.space lists RxSight, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.

What was RxSight's revenue last year?

$134.5 million for the fiscal year ended Dec 31, 2025, as reported to the SEC.

Is RxSight profitable?

RxSight, Inc. reported a net loss of $38.9 million for the fiscal year ended Dec 31, 2025, and used $15.5 million of cash in operations, per its annual report to the SEC.

How much does RxSight spend on research and development?

$38.5 million in the fiscal year ended Dec 31, 2025, per its annual report.

How much cash does RxSight have?

$208.8 million in cash and short-term investments at Jun 30, 2026, per its 10-Q.

Investor discussion: RxSight

Members talk about RxSight (RXST). Reader posts, not aibio.space reporting, and not investment advice.

Rules

Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
Say whether you hold the stock. Every post states long, short or no position.
No paid or sponsored posts. Do not post for anyone who pays or rewards you.
No buy or sell calls and no price targets.
No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
No personal details and no spam. No links at all for your first 7 days as a member.

Posts that break the rules may be deleted without notice, and the account restricted or closed. See the terms and the privacy policy.

Capital-markets timeline

Financings, listing notices, splits, legal actions and other investor events at RxSight, newest first. Each line links the filing it comes from.

Aug 10, 2026Financings
Offered to buy back its own securities. SEC Form SC TO-I. Source

Stock chart

Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. Open NASDAQ:RXST on TradingView.

Listing details

Company: RxSight, Inc.
Ticker: RXST
Listing: NASDAQ
Country or territory: United States

Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. Tell us about a change. Work at this company? Claim this page.

Published and maintained by aibio.space. Not investment advice. How we work.

Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction